Definition of a FoxA1 cistrome that is crucial for G 1 to S-phase cell-cycle transit in castration-resistant prostate cancer

Chunpeng Zhang, Liguo Wang, Dayong Wu, Hongyan Chen, Zhong Chen, Jennifer M. Thomas-Ahner, Debra L. Zynger, Jérôme Eeckhoute, Jindan Yu, Jun Luo, Myles Brown, Steven K. Clinton, Kenneth P. Nephew, Tim H.M. Huang, Wei Li, Qianben Wang

Research output: Contribution to journalArticlepeer-review

67 Scopus citations

Abstract

The enhancer pioneer transcription factor FoxA1 is a global mediator of steroid receptor (SR) action in hormone-dependent cancers. In castration-resistant prostate cancer (CRPC), FoxA1 acts as an androgen receptor cofactor to drive G 2 to M-phase cell-cycle transit. Here, we describe a mechanistically distinct SRindependent role for FoxA1 in driving G 1 to S-phase cell-cycle transit in CRPC. By comparing FoxA1 binding sites in prostate cancer cell genomes, we defined a codependent set of FoxA1-MYBL2 and FoxA1-CREB1 binding sites within the regulatory regions of the Cyclin E2 and E2F1 genes that are critical for CRPC growth. Binding at these sites upregulate the Cyclin E2 and Cyclin A2 genes in CRPC but not in earlier stage androgen-dependent prostate cancer, establishing a stage-specific role for this pathway in CRPC growth. Mechanistic investigations indicated that FoxA1, MYBL2, or CREB1 induction of histone H3 acetylation facilitated nucleosome disruption as the basis for codependent transcriptional activation and G 1 to S-phase cell-cycle transit. Our findings establish FoxA1 as a pivotal driver of the cell-cycle in CRPC which promotes G 1 to S-phase transit as well as G 2 to M-phase transit through two distinct mechanisms.

Original languageEnglish (US)
Pages (from-to)6738-6748
Number of pages11
JournalCancer Research
Volume71
Issue number21
DOIs
StatePublished - Nov 1 2011

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Definition of a FoxA1 cistrome that is crucial for G <sub>1</sub> to S-phase cell-cycle transit in castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this